drugset / Trial / NCT05496595
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2022-10-26
- Primary completion
- 2024-02-05
- Completion
- 2024-02-05
Outcome
Outcome not reported
Stopped: “Review of Data, and our other compound is a better option”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCBY02 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.